Francesca Cavallaro,Wilma Barcellini,Bruno Fattizzo
Francesca Cavallaro
Introduction: Autoimmune hemolytic anemia (AIHA) treatment has been revolutionized by the introduction of target therapies, mainly monoclonal antibodies (MoAbs). ...
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway [0.03%]
挪威免疫介导性炎症性疾病患者使用生物类似品肿瘤坏死因子抑制剂的经验教训
Guro L Goll,Tore K Kvien
Guro L Goll
Introduction: TNF inhibitors (TNFi) are in widespread use to treat a range of immune-mediated inflammatory diseases. However, the use of less expensive, biosimilar versions of these costly agents varies considerably aroun...
Lisa K Stamp,Angelo Gaffo
Lisa K Stamp
Helen Y Xu,Jamie O Yang,Phillip H Chen et al.
Helen Y Xu et al.
Introduction: Hepatitis delta virus (HDV) causes acute and chronic liver disease that requires the co-infection of the Hepatitis B virus and can lead to significant morbidity and mortality. Bulevirtide is a recently intro...
Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting [0.03%]
双特异性抗体作为单一疗法或联合用药治疗血液系统恶性肿瘤：EHA 2023年会最新资讯
Xingchen Li,Peng Zhang,Hao Sun et al.
Xingchen Li et al.
According to recent research, bispecific antibodies (BsAbs) are a promising new immunotherapy method. Various BsAb forms are constantly being developed. In the year 2022 alone, four BsAbs (tebentafusp, faricimab, mosunetuzumab, and teclista...
Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients? [0.03%]
药理学干预可以预防或延迟银屑病患者的关节炎发病吗？
Marta Loredo,Ignacio Braña,Rubén Queiro
Marta Loredo
Yaron Shoham,Yuval Krieger,Jeremy Goverman
Yaron Shoham
Introduction: Accurate burn depth assessment and early excision of burn eschar with maximal dermal preservation are key concepts in the optimal care of burn injury. Although excision with knife has long since been standar...
Ilana Schlam,Paolo Tarantino,Sara M Tolaney
Ilana Schlam
Introduction: The development of antibody-drug conjugates (ADCs) have revolutionized treatment for breast cancer. Sacituzumab govitecan (SG), a Trop2-targeted ADC, has demonstrated remarkable efficacy in triple-negative b...
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis [0.03%]
特发性肺纤维化获批及新兴抗体药物疗法最新综述
Jacopo Simonetti,Giacomo Sgalla,Luca Richeldi
Jacopo Simonetti
Introduction: The use of pirfenidone and nintedanib in treating Idiopathic Pulmonary Fibrosis (IPF) has shown significant slowing down of the progressive functional decline in these patients. In recent times, antibody-bas...
Evan G Gross,Mohammad A Hamo,Dagoberto Estevez-Ordonez et al.
Evan G Gross et al.
Introduction: Many pediatric patients with malignant tumors continue to suffer poor outcomes. The current standard of care includes maximum safe surgical resection followed by chemotherapy and radiation which may be assoc...